Skip to main content

Table 1 Characteristics of cancer patients from the clinic database selected for data analysis: number of subjects, sex, age range, weight range, and average ascorbate concentrations before and immediately after the first 15 gram IVC infusion

From: Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients

Cancer type N M/F Age (years) Weight (lbs) Ascorbic acid, post (mM) Ascorbic acid, pre (mM) Ascorbic acid, minimum pre (mM)
Bladder 10 8/2 32–80 160–192 5.00 0.078 0.045
Brain 12 3/9 26–66 126–137 6.73 0.051 0.045
Breast 105 1/133 38–72 104–190 6.57 0.076 0.023
Breast, metastatic 28 0/28 36–64 93–250 5.45 0.060 0.017
Chronic Lymphocytic Leukemia 15 8/7 50–67 125–213 5.52 0.059 0.023
Colon 34 23/11 50–78 110–280 5.46 0.063 0.017
Colon, metastatic 26 16/10 50–69 106–200 6.23 0.062 0.028
Esophagus 5 5/0 48–77 ND 5.99 0.080 0.068
Esophagus, metastatic 5 5/0 50–63 114–280 6.11 0.055 0.011
Liver 8 5/3 14–58 99–157 5.78 0.057 0.034
Liver, metastatic 7 3/4 50–69 85–160 5.90 0.052 0.028
Lung 43 25/18 49–75 104–290 5.81 0.051 0.011
Lung, metastatic 20 10/10 25–78 107–178 5.07 0.060 0.017
lymphoma (non-Hodgkin’s) 6 1/5 40–65 120–159 5.13 0.077 0.063
Melanoma 11 3/8 26–72 130–207 5.26 0.068 0.063
Ovarian 36 0/36 31–76 108–217 6.59 0.058 0.017
Pancreas 16 11/5 58–80 149–200 5.65 0.051 0.028
Pancreas, metastatic 11 7/4 65–80 132–174 5.13 0.068 0.045
Prostate 64 64/0 59–89 147–250 5.61 0.063 0.017
Prostate, metastatic 7 7/0 59–88 150–225 4.64 0.059 0.023
Renal 17 10/7 51–76 72–229 6.08 0.055 0.040
Renal, metastatic 13 7/6 39–68 ND 5.89 0.063 0.040
Sarcoma 7 5/2 21–75 90–163 4.98 0.045 0.023
Skin 6 6/0 54–76 175–211 5.54 0.051 0.028
Stomach 5 4/1 33–77 ND 4.75 0.051 0.028
Throat 7 4/3 34–80 ND 5.40 0.063 0.034
Thymus 7 4/3 48–73 48–73 5.39 0.068 0.051
Uterus 7 0/7 52–70 99–173 6.62 0.068 0.051